TRANCOPAL Drug Patent Profile
✉ Email this page to a colleague
When do Trancopal patents expire, and what generic alternatives are available?
Trancopal is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in TRANCOPAL is chlormezanone. There is one drug master file entry for this compound. Additional details are available on the chlormezanone profile page.
Summary for TRANCOPAL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 93 |
Patent Applications: | 1,092 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRANCOPAL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TRANCOPAL
US Patents and Regulatory Information for TRANCOPAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | TRANCOPAL | chlormezanone | TABLET;ORAL | 011467-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | TRANCOPAL | chlormezanone | TABLET;ORAL | 011467-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |